Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 03, 2022 06:50 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
June 02, 2022 06:50 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted...
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
May 10, 2022 06:55 ET
|
Myovant Sciences, Inc.
Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4...
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
April 29, 2022 19:10 ET
|
Myovant Sciences, Inc.
ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European commercialization partner ahead of...
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
April 12, 2022 00:00 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for...
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
February 25, 2022 09:00 ET
|
Myovant Sciences, Inc.
CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive...
Myovant Sciences to Present at Upcoming Investor Conferences
February 07, 2022 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief...